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Abstract Cyclic guanosine 3′,5′-monophosphate (cGMP)
serves as a second messenger molecule, which regulates
pleiotropic cellular functions in health and disease. cGMP is
generated by particulate or soluble guanylyl cyclases upon
stimulation with natriuretic peptides or nitric oxide, respec-
tively. Furthermore, the cGMP concentration is modulated by
cGMP-degrading phosphodiesterases. Several targets of
cGMP are utilized to effect its various cellular functions.
These effector molecules comprise cGMP-dependent protein
kinases,ion channels, and phosphodiesterases.During the last
decade, it emerged that cGMP is a novel drug target for the
treatment of pulmonary and cardiovascular disorders. In this
respect, several drugs were developed, which are now in
clinical phase studies for, e.g., pulmonary hypertension
or cardiovascular diseases. These new drugs act NO-
independently with/without heme on soluble guanylyl
cyclases or induce subtypes of particular guanylyl cyclases
and thereby lead to new therapeutic concepts and horizons. In
this regard, the fifth cGMP meeting held in June 2011 in
Halle, Germany, comprised the new therapeutic challenges
with the novel functional and structural concepts of cGMP
generatingandeffectormolecules.Thisreportsummarizesthe
new data on molecular mechanisms, (patho)physiological rel-
evance, and therapeutic potentials of the cGMP signaling
system that were presented at this meeting.
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The second messenger cyclic GMP (cGMP) is known over
50 years, but its general recognition was overshadowed for a
long time by the second messengers cyclic AMP and Ca
2+.
Interest in cGMP increased when it was discovered that NO
activates soluble guanylyl cyclase and raises thereby intra-
cellular cGMP concentrations. Soon thereafter, it was found
that organic nitrates, compounds that were used to treat
angina pectoris, released NO and enhanced cellular cGMP
levels. Already in the early 1970, the first target of cGMP
was identified, cGMP-dependent protein kinase (cGK), and
15 years later, the second target, the cGMP-gated ion chan-
nel in the retina, the first described cyclic nucleotide-gated
ion channel (CNG channel). About this time, it was known
that cGMP could regulate the cellular concentration of
cAMP through several phosphodiesterases (PDEs).
Between 1980 and 1985, it was shown that the atria released
a peptide, now known as atrial natriuretic peptide (ANP)
that caused diuresis and blood pressure lowering by activa-
tion of the particulate guanylyl cyclase, a membrane bound
enzyme, which is not activated by NO. Since then, it became
clear that the cGMP signaling machinery is an important
regulatory system in human conditions such as fear process-
ing, cerebellar motor control, pulmonary hypertension, car-
diac failure, hypertension, and erectile dysfunction. The
rapidly expanding cGMP field had its first successful gath-
ering in 2003 that suggested that new compounds may be
available that elevated cellular cGMP levels and could
emerge as valuable new therapeutic options in some of the
above mentioned diseases. Since then, the cGMP field de-
veloped significantly by the analysis of various mouse mod-
els, crystal structures, and new regulatory pathways
modulated by oxygen radicals. In 2011, the fifth cGMP
symposium was held in Halle (Saale), Germany (www.
cyclicgmp.net). This report summarizes the new data on
molecular mechanisms, (patho)physiological relevance,
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that were presented at this meeting. We apologize to our
colleagues whose contributions were not enclosed because
of space limitations.
Clinical importance of the particulate guanylyl cyclase /
cGMP signaling pathway
Particulate guanylyl cyclases (pGC) are plasma membrane
integrated natriuretic peptide receptors, which contain an
extracellular ligand-binding domain, a single transmem-
brane region, and an intracellular guanylyl cyclase domain
(Fig. 1). pGC comprise a protein family of at least seven
receptors (GC-A through GC-G) with a diverse natriuretic
peptide interaction profile (Nishikimi et al. 2011). GC-A is
stimulated by atrial and B-type natriuretic peptide (ANP and
BNP), whereas GC-B is activated by C-type natriuretic pep-
tide (CNP), and GC-C is initiated by guanylin and uroguany-
lin(Kuhn2009).Hence,thedifferentnatriureticpeptidesexert
diverse physiological functions. ANP and BNP regulate car-
diovascular homeostasis. In this regard, BNP and its N-
terminal fragment NT-proBNP is a sensitive diagnostic and
prognostic marker for heart failure and kidney diseases (Taub
et al. 2010). CNP is also involved in cardiovascular function
(Afzal et al. 2011). Additionally, CNP augments bone growth
as revealed in CNP
−/− and GC-B
−/− mice (Yasoda and Nakao
2010). Using transgenic and knockout mice, Kazuwa Nakao
(Kyoto, Japan) has elucidated that CNP is a potent stimulator
of endochondral bone growth. In humans, loss-of-function
mutations in the gene coding for GC-B have been proved to
be the cause of acromesomelic dysplasia. Following these
results, he has started to translate the stimulatory effect of
CNP on endochondral bone growth into the therapy for
patients with skeletal dysplasias. Nakao has shown that tar-
geted overexpression of CNP in cartilage or systemic admin-
istration ofCNPreversesthe impairedskeletalgrowthofmice
model of achondroplasia, the most common form of human
skeletal dysplasias.
Nesiritide, a recombinant form of human BNP, is approved
for use in the treatment of heart failure in the USA (Boerrigter
et al. 2009). However, despite its favorable cardiorenal prop-
erties (e.g., natriuresis, diuresis, inhibition of renin and aldo-
sterone, antihypertrophic, antifibrotic effects, etc.), BNP also
serves as a potent vasodilator and may decrease renal perfu-
sion and compromise renal function in heart failure patients.
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Fig. 1 Overview of cGMP signaling from their generation to their
effects. An increase in cGMP can be achieved by endogenous cGMP
generators (brown) or by cGMP-modulating drugs (blue). The targets
(green) of cGMP can regulate downstream pathways and cellular
functions (smooth muscle relaxation, platelet inhibition, cell growth
and differentiation, bone growth). This suggests potential (yellow box)
and established indications for cGMP-elevating drugs (blue). ANP/BNP/
CNP atrial/B-type/C-type natriuretic peptide, CD-NP cenderitide, sGC
soluble guanylyl cyclase, pGC particulate guanylyl cyclases, CNG chan-
nel cyclic nucleotide gated ion channel, PDEs phosphodiesterases, cGKs
cGMP-dependent protein kinases
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properties. John Burnett (Rochester, NY, USA) described a
chimeric NP, CD-NP (cenderitide), comprising CNP-22 and
the C terminus of Dendroaspis NP (DNP) (McKie et al. 2010)
(Fig. 1). CD-NP activates GC-A and GC-B receptors,
increases natriuresis, urinary flow, and glomerular filtration
rate, yet is less hypotensive than BNP. In patients with acute
heart failure, continuous infusion of CD-NP unloaded the
heart without altering blood pressure. Therefore, designer
NPs offer advantages over natural NPs and may represent a
novel therapeutic strategy in the treatment of heart failure.
Natriuretic peptides are degraded by neprilysin (NEP)
(Fig. 1). Hence, increasing the concentration of natriuretic
peptides through neprilysin inhibition represents a potential
therapeutic approach for cardiac, vascular, and renal protec-
tion (Ruilope et al. 2010). However, the clinical benefits can
be increased by simultaneous inhibition of NEP and the
renin–angiotensin–aldosterone system. LCZ696 is a first-
in-class angiotensin receptor neprilysin inhibitor, which
inhibits concomitantly NEP and the angiotensin receptor.
Martin Lefkowitz (East Hanover, USA) presented the blood
pressure lowering effects of LCZ696 in a large phase II
study in hypertensive patients (Ruilope et al. 2010). In
chronic heart failure, patients treated with LCZ696 in-
creased plasma cGMP levels while decreasing plasma NT-
proBNP and plasma aldosterone levels. An ongoing phase
III study (PARADIGM-HF) evaluates whether LCZ696 is
superior to enalapril in delaying the time to cardiovascular
mortality or hospitalization in patients with heart failure.
Dual inhibition of neprilysin and the angiotensin receptor
with LCZ696 may represent an attractive therapeutic ap-
proach for a range of cardiovascular diseases, including
hypertension and heart failure.
Hypertension is still a major cause for stroke, heart fail-
ure, myocardial infarction, and chronic kidney disease.
Blood pressure setting includes hereditary features, but ge-
netic factors have been difficult to identify at the population.
Human genetic studies could indicate novel physiological
mechanisms that underlie blood pressure. Christopher
Newton-Cheh (Boston, MA, USA) used a candidate gene
association study of common variants across the NPPA-
NPPB locus to identify genetic variants that influence atrial
natriuretic peptide (ANP) and B-type natriuretic peptide
(BNP) level (Kato et al. 2011; Newton-Cheh et al. 2009a,b).
The minor alleles of three noncoding SNPs were associated
with higher amounts of ANP and BNP in 14,515 individuals
of European ancestry. Two alleles correlating with higher
ANP/BNP concentrations were associated with lower systolic
and diastolic blood pressure as well as lower odds of hyper-
tension in 29,717 individuals. Thus, the ANP-BNP/pGC/
cGMP axis is important in the regulation of BP in humans
(Ehret et al. 2011). Further ongoing genome wide association
studies (GWAS) have identified additional novel gene loci.
These findings provide new insights into the genetics and
biology of blood pressure regulation and suggest potential
novel therapeutic pathways for cardiovascular disease
prevention.
Clinical importance of the soluble guanylyl cyclase/
cGMP signaling pathway
Soluble guanylyl cyclases (sGC) are intracellularly located
heterodimers consisting of an α-subunit (α1o rα2) and a
heme-containing β-subunit (β1o rβ2). The α1β1 and the
heterodimer is the dominantly found sGC in most tissues,
whereas α2β1 is the major sGC in brain, uterus, and pla-
centa. NO activates sGC by binding to the heme-moiety and
thereby inducing cGMP synthesis. The search of new drugs
that enhance sGC activity lead to two different classes of
compounds: sGC stimulators, which act NO independently
and heme dependently, and sGC activators, which function
NO and heme independently.
Riociguat is the first drug of the sGC stimulators (Stasch
et al. 2011) (Fig. 1). Riociguat has a dual mode of action: It
sensitizes sGC to the body’s own NO and can also increase
sGC activity in the absence of NO, causing vasorelaxation,
antiproliferation, and antifibrotic effects. This is thought to
be important because the NO levels in the pulmonary circu-
lation are decreased in patients with pulmonary hyperten-
sion (PH). With its novel mode of action, riociguat improves
cardiac and pulmonary hemodynamics and has the potential
to overcome the limitations of currently approved pulmo-
nary arterial hypertension (PAH) therapies and holds prom-
ise in other forms of PH, where no treatment is approved
including chronic thromboembolic pulmonary hypertension
(CTEPH), PH within left ventricular disease, and PH within
interstitial lung disease (PH-ILD). Riociguat is an orally
active sGC stimulator that has been shown to have a favor-
able tolerability profile. Jürgen Behr (Bochum, Germany)
presented the results of riociguat in phase II clinical trial in
PAH and CTEPH (Ghofrani et al. 2010) as well as in PH
within chronic obstructive pulmonary disease (PH-COPD)
(Ghofrani et al. 2011) and PH-ILD (Hoeper et al. 2010). The
results of these studies suggest that riociguat is a potential
treatment option for all of these diseases. As a result, phase
III clinical trials have been launched for PAH and CTEPH.
Marco Guazzi (Milano, Italy) further confirmed the impor-
tance of elevating myocardial cGMP in the treatment of
diastolic heart failure demonstrating an ability of the PDE5
inhibitor, sildenafil, to show reduction in pulmonary vascular
tone and RV hemodynamic burden. Significantly improved
pulmonary hemodynamics, right ventricular contractility, and
chamber dimensions were observed at 6 and 12 months of
follow-up,whichwasparalleledbyanimprovementinquality
of life and clinical status (Guazzi et al. 2011). Further large-
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whether PDE5 inhibition may effectively impact the appear-
ance of heart failure due to diastolic origin.
Intravascular red cell hemolysis affects NO-redox homeo-
stasis and causes endothelial dysfunction, platelet activation
and vasculopathy. The released cell-free plasma hemoglobin
reacts with NO in a 1:1 ratio (Donadee et al. 2011). This NO
consumption alters vascular function in subjects with sickle
cell anemia. Marc Gladwin (Pittsburg, PA, USA) investigated
the therapeutic potential to bypass NO scavenging via direct
pharmacological induction of sGC. He showed that sGC acti-
vators or sGC stimulators could reverse free-hemoglobin-
mediated vasoconstriction. The results propose new mecha-
nisms for endothelial injury and impaired vascular function
associated with red blood cell storage lesions and hemolysis.
Furthermore, theses studies might indicate a new therapeutic
approach restoring cGMP levels during conditions, which
excite NO scavenging.
Oleg Evgenov (Boston, MA, USA) suggested that stim-
ulation of sGC might represent a new modality for treating
pulmonary fibrosis and related conditions as patients with
pulmonary fibrosis develop pulmonary hypertension (PH),
in part due to impaired production of endogenous NO that
activates sGC. Pharmacological stimulation of sGC with
riociguat attenuates pulmonary fibrosis, PH, right ventricu-
lar hypertrophy, and mortality in bleomycin-exposed mice
(Evgenov et al. 2011).
An extraordinary Evening Lecture has been presented by
Paul Vanhoutte (Hongkong, China) on endothelial dysfunc-
tion and vascular disease. Endothelial cells regulate vascular
tone by releasing various contracting and relaxing factors
including NO, arachidonic acid metabolites (derived from
cyclooxygenases, lipoxygenases, and cytochrome P450
monooxygenases), reactive oxygen species, and vasoactive
peptides. Additionally, another pathway associated with the
hyperpolarization of the underlying smooth muscle cells
plays a predominant role in resistance arteries. Endothelial
dysfunction is a multifaceted disorder, which has been as-
sociated with hypertension of diverse etiologies involving
not only alterations of the NO/sGC/cGMP pathway but also
reduced endothelium-dependent hyperpolarizations and en-
hanced production of contracting factors, particularly vaso-
constrictor prostanoids. Vanhoutte (2009) highlighted these
different endothelial pathways as potential drug targets for
novel treatments in hypertension and the associated endo-
thelial dysfunction and end-organ damage.
Structures of key members of the GC/cGMP signaling
pathway
New insights were elucidated in the protein structures and
regulatory pathways of the GC/cGMP system, which
enhance the understanding of the (patho)physiological con-
sequences of this signaling pathway. Mammalian soluble
guanylyl cyclase (sGC) is a heterodimer consisting of an
α-a n dβ-subunit (see above). The C terminus of each
subunit includes a catalytic domain, and the active site is
arranged from both subunits. The subunits contain a PAS-
like domain and a predicted helical region
, (Derbyshire and
Marletta 2009; Mergia et al. 2009). N-termini of α- and β-
subunits are homologous to the H-NOX (heme-nitric oxide/
oxygen) family of proteins. The N terminus of the β-subunit
contains a ferrous heme cofactor acting as a NO receptor.
Ferric heme-oxidized sGC has low activity. The NO com-
plex of the re-reduced heme generates a desensitized, low-
activity state of sGC. The molecular mechanism for this
desensitization involves site specific S-nitrosation. sGC
activation induce slight and complex conformational
changes, which are still only partially understood. Some
insights were revealed by analyzing the complexes of
cinaciguat (BAY 58-2667), a sGC activator, bound to
Nostoc H-NOX domain, a homolog of sGC (Martin et
al. 2010). Heme forms a covalent inhibitory bond between
the Fe and H105 that is part of the αF helix. Cinaciguat
does not form this covalent bond yet mimics the rest of
the heme features and activates the heme free sGC.
Cinaciguat is in this respect similar to protoporphyrin IX
that lacks Fe, but is also a good sGC activator. These
insights are crucial for the understanding of the action of
the new drugs. Hence, further detailed structural and
mechanistic analysis will be an important field to enhance
the knowledge of sGC physiology.
Much more information is available for protein kinases,
which are one of the targets of cGMP. As these kinases are
so important not only for physiology but also for disease
phenotypes, many kinase structures have now been solved.
Our understanding of the structure–function relationship of
these enzymes is based on the two seminal papers by Susan
Taylor on the structure of cAMP kinase (Knighton et al.
1991; Su et al. 1995). Mammalian protein kinases are highly
regulated and are molecular switches that can be turned on
and off by various signals. Each kinase consists of two
structurally and functionally distinct lobes, the N- and the
C-lobe (Taylor and Kornev 2011). The N-lobe contains the
ATP binding site and moves upon activation to the C-lobe
that harbors the catalytic machinery that transfers the γ-
phosphate from the ATP to the substrate peptide. The struc-
tures are conserved in all mammalian kinases. They contain
an activation loop that is regulated by phosphorylation in
ways that are unique for each kinase. Early results on the
assembly of cAMP kinase, a tetramer of two regulatory and
two catalytic subunits, were discussed. We are at the begin-
ning to understand the supramolecular complexes of cAMP
kinase, A kinase anchoring proteins (AKAPs), and their
specific localization.
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were an excellent introduction to the following talks on
partial structures of cGKI. cGKI is widely expressed in
mammalian tissues and modulates a number of biological
readouts including vasodilation, motility, and memory
(Hofmann et al. 2009). cGKI is a homodimer. Large con-
formational changes are induced by the cooperative binding
of cGMP (Alverdi et al. 2008; Zhao et al. 1997). cGKI is
preferentially activated by cGMP at approximately 100-fold
lower concentrations than cAMP. cGK can be specifically
stimulated in cells and tissues upon exogenous application
of lipophilic membrane permeable cGMP analogues (Werner
et al. 2011). So far, only the structure of the amino-terminal
dimerization domain (aa 1–55 of cGKIβ) has been solved
(Casteel et al. 2010). This study confirmed the leucine zipper
structure of the dimerization site (Landgraf et al. 1990). Kim
and colleagues investigated the interaction between a crystal
ofthe cGMPbinding siteA ofcGKIβ with cAMPand cGMP.
Both nucleotides bind to the structure with a two-fold prefer-
encefor cGMP. Interestingly, cGMPbinds inthe syn,w h e r e a s
cAMPbindsinthesynoranticonfiguration.Otherpartsofthe
kinase are needed to yield cyclic nucleotide specificity. This
problem was investigated by Dostmann’s group that reported
the crystal structure of a regulatory domain fragment (aa 78–
355 of cGKIα). The fragment encloses the tandem cGMP
binding sites (Osborne et al. 2011). The structure contains
two separated cGMP binding sites connected by a central
helix. The structure revealed a previously unknown helical
domain, named switch helix that promotes the assembly of
two cGKIα78-355 protomers. Evidence was presented that
the switch helix is the critical structure for communication
between both subunits. Furthermore, it was suggested that the
cGMP binding sites of protomer A regulate the catalytic
domain of protomer B.
Signaling in the cardiovascular system through cGMP
and cGKI
Up to the cGMP 2009 meeting in Regensburg (Germany),
an unresolved question was whether or not a heme-free sGC
exists in vivo. This enzyme cannot be activated in vivo by
NO but should respond to the sGC activator cinaciguat.
Generation of a heme-free sGC would allow to differentiate
physiological functions of NO that are mediated by sGC and
that are mediated by radicals (ROS). Peter Brouckarts group
in Ghent generated a mouse in which histidine 105 of the
β1sGC subunit was mutated to a phenylalanine (apo-sGC).
The sGC of this mouse line does not respond to NO but does
still respond to cinaciguat demonstrating that a heme-free
sGC can exist in vivo. This is an excellent proof for the
pharmacological significance of sGC activators in humans.
NO-dependent effects that need an intact sGC are blood
pressure regulation and inhibition of platelet aggregation.
In addition, basal sGC activity is essential for life because
mice carrying the apo-sGC mutation die premature (t
1/20
30 weeks). sGC is required for relaxation of vascular and
stomach smooth muscle but not for relaxation of colon
smooth muscle. Further complicating this field was the
observation that mice with an intestinal smooth muscle
specific deletion of the β1sGC show “normal” NO/8 Br-
cGMP-dependent relaxation (Groneberg et al. 2011). Even
more surprising was the report that β1sGC-KO mice have
no NO/8 Br-cGMP-dependent relaxation of the corpus cav-
ernosum but are fertile at a normal level confirming a
previous finding with cGKI-KO mice (Hedlund et al. 2000).
The focus shifted to the important question: Are cGMP
and cGKI protective in cardiac ischemia and hypertrophy?
Previous work suggested that cardiomyocyte cGMP and
cGKI are essential (Burley et al. 2007;T a k i m o t oe ta l .
2005). Justin Bice (Cardiff) showed that stimulation of
cardiac sGC limits infarct size. More differentiated experi-
ments using cardiomyocyte-specific deletion of cGKI and a
postconditioning protocol after ischemia revealed that only
treatment with cinaciguat required cGKI, whereas treatment
with an A2B receptor agonist and the mitochondria-targeted
S-nitrothiol (MitoSNO) were not affected by the absence of
cGKI. These findings suggest that the beneficial effects of
ischemic postconditioning, activation of the A2B receptor
and the direct NO effects via mitochontrial S-nitrosylation
are independent of cardiomyocyte cGKI (Krieg, Cambridge).
However, cGKI is required to reduce kidney fibrosis induced
by ureter ligation (Schlossmann, Regensburg). Eiki Takimoto
(Baltimore, MD, USA) reexamined by which mechanism
enhanced cGMP-cGKI signaling by PDE5 inhibitor sildenafil
ameliorates cardiac maladaptive hypertrophy/remodeling
(Takimoto et al. 2005). He concluded from extensive studies
that enhanced cGMP-cGKI signaling by sildenafil improves
cardiac energetic by restoring mitochondrial respiration a
finding that fits to the hypothesis that cGKI (but see results
of Krieg) improves mitochondrial respiration by an unknown
mechanism. Enrico Patrucco, (München, Germany) showed
very convincing results that sildenafil may affect myofibro-
blast but not cardiomyocyte functions, a result that is in line
with the finding that PDE5 is not present in cardiomyocytes,
but in cardiofibroblasts (Lukowski et al. 2010).
These results were extended by Philip Eaton (London,
UK)andBeateSpießberger(München,Germany).Oxidationof
cysteine42ofGKIαactivatesthekinase(Burgoyneetal.2007).
A mouse line, in which Cys42 is mutated to a serine, is hyper-
tensive (Prysyazhna et al. 2012). Vascular cGKIα is not acti-
vated by H2O2 in these mice, indicating that eventually redox
regulation of the kinase is a physiological event and prevents
hypertension.Evenmoresurprisingwasthereportthatneuronal
cGKI is required to allow proton induced bicarbonate secretion
in the duodenum. Neuronal cGKI-KO mice develop duodenal
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ized (Singh et al. 2012). Michael Mendelsohn, now at Merck
& Co, gave an intriguing and lively talk on the importance of
cGKIforcardiovascularphysiology.HepointedoutthatcGKI
haveseveral targetsincluding ion channels, G protein coupled
receptors, SR proteins, protein phosphatase subunits, regula-
tors of G proteins, and small G proteins. The variety of these
targets allows a variable regulation of cellular and organ
functions as needed by the organism. He also showed that
MerckisdevelopingsGCstimulatorsandsGCactivatorstobe
used for the treatment of pulmonary hypertension, heart fail-
ure, and other diseases. The competition for the best com-
pounds and treatment is now open (Stasch et al. 2011).
Other functions of cGMP
NO/cGMP has diverse functions in various systems includ-
ing the cardio-vasculature, neurotransmission, inflamma-
tion, and cell death. This part of the meeting covered some
of the emerging roles of this pathway.
Sildenafil is an inhibitor of the cGMP-specific phospho-
diesterase type 5 (PDE5), which was launched by Pfizer in
1998. The first indication was erectile dysfunction. Later, it
was also approved for treating pulmonary hypertension.
Interestingly, sildenafil may also have cardioprotective
effects in the mdx mouse. The mdx mouse lacks dystrophin
and develops cardiac dysfunction as humans with Duchene
muscular dystrophy (DMD). DMD is caused by lack of
dystrophin (Finsterer and Stollberger 2003) that prevents
nNOS expression and signaling. It was therefore likely that
increasing cGMP levels might alleviate the symptoms of
DMD (Adamo et al. 2010). Joseph Beavo (Washington, DC,
USA) reported that, in contrast to sildenafil, the specific
PDE5 inhibitor tadalafil does not mediate cardioprotection
in mdx mice. He pointed out that PDE5 is not expressed in
adult mouse cardiomyocytes, where, however, PDE1C is
highly expressed. While sildenafil at high concentrations
inhibits PDE1C, tadalafil does not. Thus, Beavo suggested
that, in cardiomyocytes, PDE1C is the target for sildenafil,
which may be applied as a preventive and curative treatment
for DMD-caused cardiomyopathy.
In the nervous system, NO acts as a retrograde messenger
that is generated postsynaptically to increase the neurotrans-
mitter release presynaptically. This role of NO is thought to
play a role in the long-term potentiation (LTP) and modula-
tion of synaptic transmission (Haghikia et al. 2007). The
group of Doris Koesling (Bochum, Germany) investigated
the role of sGC in this process. Both α1 and α2 isoforms of
sGC are expressed in glutamatergic and GABA-ergic neu-
rons, and deletion of both α-isoforms in mice abolished LTP
in the hippocampus and visual cortex. Interestingly, presyn-
aptic glutamate release was only reduced in sGC α1K O
mice, whereas a reduction of postsynaptic NMDA receptor
currents was only observed in sGC α2 KO mice. Koesling
further suggested that eNOS is the source of NO mediating
presynaptic glutamate release, which interacts with signal-
ing through an α1-dependent sGC via cGMP to open
hyperpolarisation-activated cyclic nucleotide-gated chan-
nels (Neitz et al. 2011).
Another emerging gaseous transmitter, besides NO and
CO, with close relations to cGMP is hydrogen sulfide (H2S).
Andreas Papapetropoulos (Patras, Greece) reported on the
regulation of vascular growth and tone by H2S. In blood
vessels, H2S is endogenously synthesized from L-cysteine
by the two enzymes cystathionine-synthase (CBS) and
cystathionine γ-lyase (CSE). CBS is highly expressed
in the central nervous system, while CSE is abundantly
present in the heart, lung, blood vessels, liver, and kidney.
Cardiovascular functions of H2S include antiapoptotic
effects on cardiomyocytes, cardioprotective actions, and
altered vascular tone (Suzuki et al. 2011). Exogenously
administered Na2S stimulates endothelial proliferation, mi-
gration, and capillary-like network formation. Vascular en-
dothelial growth factor (VEGF) increased H2S production in
endothelial cells, and genetic or pharmacological CSE inhi-
bition reduced VEGF-driven angiogenic responses (migra-
tion, sprouting). Thus, H2S could be a target for the
treatment of diseases with altered angiogenesis. Recently,
it was shown that H2S inhibits phosphodiesterase activity in
vitro. Furthermore, H2S increases cGMP levels in smooth
muscle cells (Bucci et al. 2010) and probably modulates
vascular tone via cGKI. Thus, H2S may play an important
role in vascular biology. The functional interactions between
NO, cGMP, and H2S were extended to the chemical level by
Akaike (Kumamoto, Japan). About 80% of H2S is present in
its anionic form, SH
−, which he claimed to be a negative
regulator of endogenously formed 8-nitro-cGMP. This
nitrated cGMP derivative reacts with protein sulfhydryls
resulting in adduction of cGMP to proteins, which is a
posttranslational modification called protein S-guanylation
(Ahmed et al. 2011). 8-Nitro-cGMP is formed from guanine
derivatives by reactive nitrogen species stemming from the
reaction of NO with ROS (Ahmed et al. 2011). In cells, SH
−
reacts with 8-nitro-cGMP generating a new electrophilic
derivative. This derivative modulates electrophilic signaling
via the oncogene H-Ras. H-Ras activation then suppressed
cellular senescence. Together, these results suggest novel
roles of H2S, i.e., interaction of its anionic form with 8-
nitro-cGMP. Via this mechanism, H2S may also attenuate
cardiac dysfunction.
Renate Pilz (San Diego) switched the topic to bone mass
and strength. In osteoblasts, fluid shear stress is a major
mechanism by which mechanical forces stimulate osteo-
blast/osteocyte growth and differentiation (Ehrlich and
Lanyon 2002). Fluid shear stress activates cGK via NO/
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genes mediated through activation of Erk1/2 (Rangaswami
et al. 2009). She reported that cGKII, but not cGKI, acti-
vates Src in mechanically stimulated osteoblasts, which
initiates a proliferative response. This process requires in-
teraction of Src with the mechanosensors of bones, the β3
integrins. It further depends on Src activation, i.e., de-
phosphorylation by Src homology 2 domain-containing ty-
rosine phosphatases (SHP) 1 and 2. SHP-1 is a novel sub-
strate that is directly phosphorylated and activated by
cGKII. Furthermore, fluid sheer stress triggers the formation
of a novel “mechanosome” composed of cGKII, Src, SHP 1
and 2, and β3 integrins. This newly discovered mechanism
of Src activation mediates Erk1/2 activation and finally bone
growth. This suggests a novel indication for cGK-activating
drugs, i.e., osteoporosis in which they may mimic the ana-
bolic effects of mechanical bone stimulation (Rangaswami
et al. 2010).
cGMP and ion channels
Endothelial NO regulates vascular tone by signaling through
sGC, cGMP, and cGK. The most important targets of cGKI
include the myosin-interacting subunit of myosin phospha-
tase 1, the regulator of G-protein signaling 2, the inositol
receptor associated cGKI-substrate (IRAG), and the BK
channel. Recent evidence suggest that TrpC channels are
also targets of cGKI in smooth muscle and mediate, at least
partially, the relaxant effects of cGMP (Chen et al. 2009;
Kwan et al. 2004; Yuasa et al. 2011). This new concept was
tested by investigating the role of cGMP/cGKI signaling on
vascular tone and peripheral resistance using cGKI-, TrpC6-
, and TrpC3 knockout mice (Wegener, München). However,
neither differences were found in the response to alpha-
adrenergic stimulation with respect to the contractility of
thoracic aorta nor to the increase in peripheral resistance.
Activation of cGKI by 8-Br-cGMP diminished aortic tone
and peripheral resistance to a similar extent in control,
TrpC6
−/−,a n dT r p C 3
−/− mice. No effect of 8-Br-cGMP
was observed in preparations from smooth-muscle specific
cGKI
−/− mice. These results therefore suggest that cGMP/
cGKI signaling in aorta and peripheral vessels from mice
does not require TrpC6 or TrpC3 channels.
Consistent with this, Michaela Kuhn (Würzburg, Germany)
reported on a novel cGMP-independent signaling pathway of
pGC-A, the receptor for atrial natriuretic peptide (ANP), in-
volving TRPC3/C6 channels (Klaiber et al. 2011). ANP regu-
latesarterial blood pressure,moderates cardiomyocyte growth,
and stimulates angiogenesis and metabolism. ANP has been
invoked to trigger a cGMP-dependent signaling pathway that
prevents pathological increases in [Ca
2+]i in cardiomyocytes.
In chronic cardiac hypertrophy, ANP levels are markedly
increased, and GC-A/cGMP responses to ANP are blunted
due to receptor desensitization. Michaela Kuhn showed that
in this situation ANP binding to pGC-A stimulates a novel
cGMP-independent signaling pathway in cardiomyocytes
resulting in pathologically elevated [Ca
2+]i. In this condition,
pGC-A forms a stable complex with TRPC3/C6 channels
resulting in TRPC3/C6-mediated Ca
2+ entry followed by stim-
ulation of calmodulin kinase II (CaMKII) to phosphorylate L-
type Ca
2+ channels leading to increased L-type Ca
2+ channel
mediated Ca
2+ current and a rise in intracellular Ca
2+ levels
(Klaiber et al. 2011). Although these observations are very
intriguing, they need confirmation by other groups because
they would suggest that treatment of heart failure with ANP/
BNP or cGMP elevating drugs may not result in alleviation of
the disturbed cardiac situation. Furthermore, under physiolog-
ical conditions, activation of a cGMP-dependent pathway
moderates the Cai
2+-enhancing action of hypertrophic factors
such as angiotensin II (Takimoto et al. 2005).
Upcoming topics
Heme oxygenase-1 (HO-1) metabolizes heme to equimolar
amounts of carbon monoxide (CO), biliverdin and ferrous
iron. CO activates sGC and thereby indirectly leads to
suppression of neointima formation after arterial injury.
Consequently, HO-1 deletion exacerbates lesion develop-
ment. William Durante and co-workers (Columbia, SC,
USA) found that induction of HO-1 or CO application leads
to increased cGMP levels and antiproliferative effects in
cultured vascular smooth muscle cells (VSMCs). The sGC
stimulator YC-1 did not only increase the antiproliferative
effect of CO in VSMCs by sGC stimulation but also by
induction of HO-1 gene expression and hence increased CO
production. This effect could also be reflected in the sup-
pression of neointima formation and increased cGMP levels
after vessel injury in vivo. However, the sGC stimulator
BAY41-2272 did not influence HO-1 gene induction. Vice
versa, HO-1 deficiency also leads to a decline in sGC
expression resulting in impaired endothelium-dependent
vasorelaxation in response to sGC stimulators and activa-
tors. In conclusion, HO-1 elicits important vasoprotective
actions by stimulating sGC activity via CO and preserving
sGC expression levels.
After showing that the development of nitrate tolerance in
vivo is in part mediated by sGC desensitization through
nitroglycerin-induced S-nitrosylation of cysteine residues
(Sayed et al. 2008), Annie Beuve (New Jersey, USA) pre-
sented data also suggesting a role for this mechanism in
cardiovascular disease development. The authors used angio-
tensin II (AT II)-induced hypertension as a model for oxida-
tive cardiovascular disease. AT II treatment induced in rats’
resistance to NO donor-mediated relaxation. Simultaneously,
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those rats and associated with decreased NO-dependent
cGMP production. Notably, sGC expression levels were un-
changed in AT II-treated compared to untreated animals.
These in vivo findings were supported by in vitro data show-
ing that especially S-nitrosation of cysteine residue 516 in the
alpha subunit of sGC mediates AT II-induced NO desensiti-
zation independent of heme oxidation. The authors therefore
propose that additional to decrease NO bioavailability this
desensitization of sGC to NO by S-nitrosation of sGC-
Cys516 contributes to the decreased vascular reactivity in
AT II-induced hypertension.
Alexander Pfeifer (Bonn) shifted the focus from vascular
diseases to obesity. The cGMP pathway can be found in
both white and brown fat cells where one of the receptors of
cGMP, cGKI, might play a major role in calorie burning in
brown fat cells. Differentiation of brown fat cells was mark-
edly suppressed in cGKI deficient mice (Haas et al. 2009),
whereas others showed that overexpression of cGKI in fat
cells leads to enhanced mitochondrial biogenesis and there-
by to prevention of obesity. cGKI is expressed in murine
white adipocytes and may be involved in the differentiation
of white adipocytes.
Roland Seifert (Hannover) took us to basic science and
draw attention to cGMP’s abandoned siblings cCMP and
cUMP. Their recent findings that bacterial “adenylyl” cy-
clase toxins also exhibit cytidylyl- and uridylyl cyclase
activity (Gottle et al. 2010) renewed the interest in this field.
To evade methodological mistakes that were done in early
years of cCMP and cUMP research, a highly sensitive
quantitative HPLC-MS/MS was used. The cyclic nucleoti-
des were detected in cultured cell and in human urine by this
method. Several cAMP and cGMP-degrading phosphodies-
terases have cUMP degrading activity (Reinecke et al.
2011), and some biological effects of cCMP and/or cUMP
were indicated in platelet aggregation (Desch et al. 2010)
and neuronal cell differentiation. Collectively, those find-
ings argue for a role of cCMP and cUMP as (old) new
endogenous second messengers (Beste et al. 2012).
Conclusion
The cGMP symposia, which are organized since 2003 every
2 years, are outstanding international meetings for research-
ers in the cGMP field in basic and clinical research. The 5th
cGMP symposium, which took place in Halle (Saale),
Germany, uncovered that the second messenger molecule
cGMP is a valuable drug target for the treatment of various
pulmonary and cardiovascular diseases (Fig. 1). Several
compounds acting on soluble guanylyl cyclases (sGC stim-
ulators and sGC activators) or particulate guanylyl cyclases
(e.g., designer natriuretic peptides or neprilysin/AT-receptor
inhibitors) were synthesized, which are now coming into
the drug pipeline. In this regard, several human trial
studies are performed for the treatment of diverse pulmo-
nary diseases, e.g., COPD, CTEPH, or other PH disor-
ders, and for the treatment of diverse forms of heart
failure (Table 1). Furthermore, research of the cGMP
generation and signaling mechanisms, structural work,
genetic and tissue models were presented and are further
needed to elucidate new compounds and novel treatment
options in the cGMP field.
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Table 1 Human trial studies described in the cGMP2011 symposium
Drug Drug target mechanism Human trial study Disease References
CD-NP Activator of GC-A/GC-B Phase II Acute heart failure McKie et al. 2010
LCZ696 Inhibition of neprilysin/
angiotensin receptor
Phase II Hypertension Ruilope et al. 2010
Phase II: PARAMOUNT Heart failure
Phase III: PARADIGM-HF
Riociguat sGC stimulator Phase II: PAH, CTEPH Ghofrani et al. 2010, 2011;
Hoeper et al. 2010 PH-COPD
PH-ILD
Phase III:
PATENT-trial PAH
CHEST-trial CTEPH
Sildenafil PDE5 inhibitor Phase II: 1 year study Heart failure Guazzi et al. 2011
GWAS analysis: ANP-BNP/
pGC/cGMP axis
Hypertension Newton-Cheh et al. 2009a, b;
Ehret et al. 2011; Kato et al. 2011
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